ArticleJournal of the American College of Cardiology2018
Genomic Risk Prediction of Coronary Artery Disease in 480,000 Adults: Implications for Primary Prevention.
Article in Journal of the American College of Cardiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 482 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pragmatic Randomized Trial of Polygenic Risk Scoring for Common Diseases in Primary Care
Polygenic Risk Score to Optimize Primary Prevention in Intermediate Risk Population (PERSONAL)
Who cites it
482 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Pooled it
- Global trajectories of polygenic risk score research: a systematic bibliometric review of precision medicine, equity, and clinical translation.Frontiers in medicine · 2026Pooled it
- Clinical analysis of drug treatment trends for coronary heart disease in China.Frontiers in medicine · 2026Pooled it
- Genetic Biomarkers for Periodontal Diseases: A Systematic Review.Journal of clinical periodontology · 2025Pooled it
- Uncovering associations between pre-existing conditions and COVID-19 Severity: A polygenic risk score approach across three large biobanks.PLoS genetics · 2023Pooled it
- Evaluating the impact of communicating high polygenic risk for coronary artery disease on the health behaviour of young overweight adults: a pragmatic randomised controlled trial.Scientific reports · 2026Trial
- Polygenic risk, aspirin, and primary prevention of coronary artery disease.European heart journal. Cardiovascular pharmacotherapy · 2025Trial
- Use of a polygenic risk score to enhance early detection of coronary atherosclerosis.American journal of preventive cardiology · 2026Article
- Polygenic risk score for early identification of coronary artery disease in a real-world clinical setting within the Latvian patient population.American heart journal plus : cardiology research and practice · 2026Article
- bioETH-PRS: confidential polygenic risk scoring with smart contracts on an FHE-enabled blockchain.Briefings in bioinformatics · 2026Article
- Integrating Conventional and Emerging Approaches in Cardiovascular Risk Assessment and Management.Public health challenges · 2026Review
- Social jet lag is associated with incident cardiovascular disease independent of sleep duration and cardiac genetic risk.Journal of internal medicine · 2026Article
- An Integrated Model of Cardiotoxicity: Interaction of Age, Sex, and Genetic Polymorphisms in Patients with Acute Leukemia.Biomedicines · 2026Article
- AI-based multimodal integration of genomics and electronic health records.Nature reviews. Genetics · 2026Review
- A multi-ancestry polygenic risk score for body mass index predicts longitudinal weight change.Genome medicine · 2026Article
- The role of polygenic risk in Alzheimer's disease prediction for African Americans.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Observational
- Performance of Polygenic Risk Scores for Atherosclerotic Cardiovascular Disease in theCirculation. Genomic and precision medicine · 2026Article
- Inherited risk of coronary artery disease: redefining care with imaging and genetics.Nature reviews. Cardiology · 2026Review
- Pervasive interactions between exposures and polygenic risk can inform more effective clinical and behavioral interventions.Nature genetics · 2026Article
- Common Single Nucleotide Polymorphisms in Clinical Cardiology and Dietary Intervention: A Narrative Review.Nutrients · 2026Review
422 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
26 authors.
Funding
Abstract
backgroundCoronary artery disease (CAD) has substantial heritability and a polygenic architecture. However, the potential of genomic risk scores to help predict CAD outcomes has not been evaluated comprehensively, because available studies have involved limited genomic scope and limited sample sizes.
objectivesThis study sought to construct a genomic risk score for CAD and to estimate its potential as a screening tool for primary prevention.
methodsUsing a meta-analytic approach to combine large-scale, genome-wide, and targeted genetic association data, we developed a new genomic risk score for CAD (metaGRS) consisting of 1.7 million genetic variants. We externally tested metaGRS, both by itself and in combination with available data on conventional risk factors, in 22,242 CAD cases and 460,387 noncases from the UK Biobank.
resultsThe hazard ratio (HR) for CAD was 1.71 (95% confidence interval [CI]: 1.68 to 1.73) per SD increase in metaGRS, an association larger than any other externally tested genetic risk score previously published. The metaGRS stratified individuals into significantly different life course trajectories of CAD risk, with those in the top 20% of metaGRS distribution having an HR of 4.17 (95% CI: 3.97 to 4.38) compared with those in the bottom 20%. The corresponding HR was 2.83 (95% CI: 2.61 to 3.07) among individuals on lipid-lowering or antihypertensive medications. The metaGRS had a higher C-index (C = 0.623; 95% CI: 0.615 to 0.631) for incident CAD than any of 6 conventional factors (smoking, diabetes, hypertension, body mass index, self-reported high cholesterol, and family history). For men in the top 20% of metaGRS with >2 conventional factors, 10% cumulative risk of CAD was reached by 48 years of age.
conclusionsThe genomic score developed and evaluated here substantially advances the concept of using genomic information to stratify individuals with different trajectories of CAD risk and highlights the potential for genomic screening in early life to complement conventional risk prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.